Raising a biotech Series A is not like raising for a software company, and founders who borrow the tech playbook tend to struggle. There is no viral growth curve to point at, no monthly recurring revenue, often no product at all, just science, a plan, and a team asking for tens of millions of dollars on the strength of a hypothesis. That makes the biotech Series A its own discipline. Here is how it actually works.
What a biotech Series A is really funding
A Series A in biotech is typically the round that takes a company from promising early data to a defined value-inflection point, the moment when the science has de-risked enough to justify a much larger Series B or a partnership. In practice that usually means funding a program from lead optimization or early preclinical work toward the clinic, or through a specific experiment that will make or break the thesis.
Investors are not buying revenue. They are buying a credible path to a milestone that will make the company meaningfully more valuable. Everything in your raise should ladder up to that: this is the milestone, this is what it costs to reach it, this is why reaching it de-risks the company.
What investors need to see
Biotech investors underwrite a specific set of things, and a Series A pitch lives or dies on how well it addresses them:
- Differentiated science. Why is this biology real, and why is your approach better than the obvious alternatives? Investors see dozens of decks; the ones that stick have a crisp, defensible scientific insight at the center.
- A clear unmet need. A great mechanism aimed at a problem nobody needs solved does not get funded. Tie the science to a real patient population and a real market.
- A killer experiment. The best raises are organized around the single experiment or milestone that will prove or disprove the thesis. Investors love a plan that is honest about its own crux.
- A team that can execute. At the earliest stages, investors bet on people as much as data. A team with relevant drug-development experience, or credible scientific founders paired with an operator, inspires confidence.
- A financing and exit logic. Who funds the next round, and what does a return look like, partnership, acquisition, IPO? You do not need certainty, but you need a coherent story.
How much to raise, and for how long
The instinct to raise as much as possible is usually wrong. Raise enough to hit your next major value-inflection point with a comfortable margin, plus runway to raise the following round from a position of strength. Running out of cash just before a key readout is the classic biotech death, because it forces you to raise on bad terms or not at all.
A useful discipline is to work backward from the milestone: cost it honestly, add a buffer for the things that always take longer and cost more, and add the months you will need to raise the next round. That number, not a round-number ambition, is your target. Timing of spend matters as much as the total; many biotechs manage cash by making fit-for-purpose decisions on early development rather than gold-plating everything.
The process, start to finish
A biotech Series A typically unfolds over three to six months, sometimes longer in a cautious market. The rough arc:
- Preparation. Get your data package, deck, and financial model in order before you talk to anyone. Investors talk to each other; a sloppy first impression is expensive.
- Targeting. Identify the ten to twenty firms whose stage and thesis genuinely fit, rather than blasting a hundred. Quality of targeting beats quantity every time.
- First meetings. These are about the story and the team. Get to the scientific insight fast; do not bury it under twenty slides of background.
- Diligence. Serious interest triggers deep scientific, technical, and market diligence. This is where a clean, honest data package pays off.
- Term sheet and close. A lead sets terms; other investors fill the round. Then weeks of legal work before the money lands.
The mistakes that sink rounds
A few failure modes recur. Pitching the wrong investors, firms that do not lead your stage or have cooled on your area, wastes months. Overselling the data, or worse, hiding its weaknesses, destroys trust the moment diligence uncovers the truth. Raising too little and running out of runway before the milestone forces a bad down round. And treating fundraising as a part-time activity while running the company almost never works; for the months you are raising, it is close to a full-time job for the CEO.
Give yourself the best odds
The founders who raise cleanly share a pattern: they prepare obsessively, target precisely, tell an honest story built around a clear milestone, and start relationships with investors long before they need the money. None of that guarantees a round, biotech is hard and markets move, but it stacks the odds.
Valuation and dilution: the founder’s real anxiety
Beneath every fundraising conversation is the question founders actually lie awake over: how much of the company will I give up? Valuation determines dilution, and dilution compounds across rounds, so the temptation is to push for the highest possible valuation now. Resist the urge to over-optimize it. A valuation set too high in a Series A can haunt you at the Series B, when you either have to grow into an aggressive number or accept a painful down round that signals weakness to the market. A fair valuation with an investor you trust, room to grow, and clean terms is usually worth more than a headline number with a difficult partner. Terms matter as much as price; a high valuation wrapped in punitive structure can be worse than a modest one with clean, standard terms.
The syndicate is part of the product
A Series A is rarely one investor; it is a syndicate, and the composition of that syndicate is itself a strategic asset. A strong lead sets terms and takes a board seat, but the other investors matter too, for the capital they can provide in future rounds, the networks they open, and the signal their names send. Building a syndicate that blends conviction, deep pockets for the next round, and relevant expertise gives your company more than money; it gives you a bench. When you evaluate an offer, look past the check size to what each investor actually brings, and to whether they will still be there, and able to write another check, when you need them at the Series B.
Get these three things right before you start
Founders often begin raising before their materials can survive contact with a sharp investor, and it costs them. Three artifacts deserve real work up front. First, a data package that is honest and clean: investors will find the weaknesses, so present them yourself, with your interpretation, rather than letting diligence surface them as surprises. Second, a deck that reaches the scientific insight within the first few slides and organizes everything around the milestone your raise will fund, not a wall of background. Third, a financial model that ties the raise to that milestone and shows you have thought realistically about what it costs and how long it takes. Getting these three right before the first meeting does more for your odds than any amount of hustle afterward, because investors talk to each other, and a strong first impression compounds across the whole syndicate.
When you get to targeting, the BioMed Nexus venture capital directory lets you filter investors by stage and type so you can build a tight list of firms that actually fund Series A rounds like yours. And the daily BioMed Nexus brief tracks who just raised a fund and who is deploying capital right now, which is exactly the intelligence that makes targeting sharp.
Frequently asked questions
How much should a biotech raise in a Series A?
Raise enough to reach your next major value-inflection milestone with a comfortable buffer, plus runway to raise the following round from strength. Work backward from the cost of the milestone, add a buffer for delays, and add the months needed for the next raise. Running out of cash before a key readout is the classic biotech mistake.
What do investors look for in a biotech Series A?
Investors look for differentiated, defensible science, a clear unmet medical need, a well-defined experiment or milestone that will prove the thesis, a team that can execute drug development, and a coherent financing and exit logic. At early stages they bet on the team and the scientific insight as much as the data.
How long does it take to raise a biotech Series A?
A biotech Series A typically takes three to six months from first meetings to close, sometimes longer in a cautious market. The process runs through preparation, investor targeting, first meetings, scientific and market diligence, and finally a term sheet and legal closing.
